Media ReleasesSUDA Pharmaceuticals

View All SUDA Pharmaceuticals News


Market Update


SUDA Pharmaceuticals Ltd (ASX: SUD), provides the following update in relation to the Company’s recent suspension. The Company had been progressing towards the announcement of a proposed material licensing transaction in relation to a promising cancer therapy technology from a leading U.S. Cancer Research Institute and, on 1 June 2020, entered into a trading halt, to finalise these arrangements and the arrangements for the proposed capital raising

For more information, please download the attached PDF
Download this document

Are you a 708 sophisticated investor?

If you are a sophisticated investor as defined under Section 708 of the Corporations Act (net assets of $2.5 million or annual incomes in excess of $250,000).

We can alert you to wholesale investment opportunities not available to regular investors.

Please subscribe if you would like to be alerted to these types of opportunities.